Action	Date	Notes	Link
article xml uploaded.	4 March 2016 11:33 CET	Original file	-
article pdf uploaded.	4 March 2016 11:33 CET	Version of Record	https://www.mdpi.com/2073-4468/5/1/6/pdf-vor
article xml uploaded.	10 March 2016 11:13 CET	Update	https://www.mdpi.com/2073-4468/5/1/6/xml
article pdf uploaded.	10 March 2016 11:13 CET	Updated version of record	https://www.mdpi.com/2073-4468/5/1/6/pdf
article html file updated	28 March 2016 11:29 CEST	Original file	-
article html file updated	26 March 2019 22:39 CET	Update	-
article html file updated	5 May 2019 22:21 CEST	Update	-
article html file updated	7 February 2020 05:29 CET	Update	https://www.mdpi.com/2073-4468/5/1/6/html

Cite

Export citation file: BibTeX | EndNote | RIS

MDPI and ACS Style

Root, A.R.; Cao, W.; Li, B.; LaPan, P.; Meade, C.; Sanford, J.; Jin, M.; O’Sullivan, C.; Cummins, E.; Lambert, M.; et al. Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer. Antibodies 2016, 5, 6. https://doi.org/10.3390/antib5010006

AMA Style

Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O’Sullivan C, Cummins E, Lambert M, et al. Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer. Antibodies. 2016; 5(1):6. https://doi.org/10.3390/antib5010006

Chicago/Turabian Style

Root, Adam R., Wei Cao, Bilian Li, Peter LaPan, Caryl Meade, Jocelyn Sanford, Macy Jin, Cliona O’Sullivan, Emma Cummins, Matthew Lambert, and et al. 2016. "Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer" Antibodies 5, no. 1: 6. https://doi.org/10.3390/antib5010006

APA Style

Root, A. R., Cao, W., Li, B., LaPan, P., Meade, C., Sanford, J., Jin, M., O’Sullivan, C., Cummins, E., Lambert, M., Sheehan, A. D., Ma, W., Gatto, S., Kerns, K., Lam, K., D’Antona, A. M., Zhu, L., Brady, W. A., Benard, S., ... Bloom, L. (2016). Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer. Antibodies, 5(1), 6. https://doi.org/10.3390/antib5010006

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

For more information on the journal statistics, click here.

Multiple requests from the same IP address are counted as one view.

Article Menu

Article Versions Notes

Further Information

Guidelines

MDPI Initiatives

Follow MDPI